Mini-CAR for HLH
Hemophagocytic Lymphohistiocytosis (HLH)
Pre-clinicalActive
Key Facts
Indication
Hemophagocytic Lymphohistiocytosis (HLH)
Phase
Pre-clinical
Status
Active
Company
About Caravan Biologix
Caravan Biologix is pioneering an AI-designed, cell-free CAR therapeutic platform using engineered biospheres derived from allogeneic cells. Its core technology, Mini-CAR, is designed to offer superior tumor penetration, reduced toxicity like cytokine release syndrome (CRS), and simplified manufacturing compared to whole-cell therapies. The company's strategy involves building an internal pipeline while actively seeking platform licensing partnerships to develop therapies for oncology and hereditary diseases.
View full company profileTherapeutic Areas
Other Hemophagocytic Lymphohistiocytosis (HLH) Drugs
| Drug | Company | Phase |
|---|---|---|
| MYD88 Epigenetic Repressor | GenexGen | Pre-clinical |